Categories AlphaGraphs, Earnings, Retail

CarMax Q3 revenue misses estimates as comparable used car sales slip

Used-car retailer CarMax (KMX) posted its third-quarter earnings on Friday, Dec. 21 before the opening bell. Top-line fell short of market expectations.

Net sales and operating revenues for the Fortune-500 company rose 4.6% to $4.30 billion, even as used-unit sales in comparable stores slipped 1.2%.

Net earnings rose 34.6% to $1.09 per diluted share or $190.3 million.

Analysts had expected earnings of $1.01 per share on revenue of $4.35 billion for the period.

For the last three months, CarMax shares have underperformed the industry, with the stock declining 12% vs. the 25% rise for the sector.

For the quarter, total used unit sales rose 2.3%, while wholesale unit sales jumped 10.0%. CarMax Auto Finance (CAF) income rose 6.7% to $109.7 million.

CarMax Q3 2019 Earnings Infographic

Net earnings for the reporting period benefitted from the decrease in the effective tax rate to 23.2% from 33.9% in the prior year’s third quarter, primarily reflecting the effect of the Tax Cuts and Jobs Act of 2017.

Compared with the third quarter of fiscal 2018, SG&A expenses rose 2.5% to $409.5 million. Continued investment in technology platforms and an 11% increase in its store base, representing the addition of 19 stores, were the reason for this rise in expenses.

During the third quarter, CarMax opened four stores, all in new television markets — Wilmington, North Carolina; Lafayette, Louisiana; Corpus Christi, Texas; and Shreveport, Louisiana.

This quarter saw the seconds’ retailer take an aggressive stance to pursue store expansion. In the first half of fiscal 2019, SG&A expenses shot up 10.3% to $891.8 million due to store openings. For fiscal 2019, CarMax had earlier projected capex of around $340 million.

 

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top